APYX

JMP Securities analyst David Turkaly reiterated a Buy rating on Apyx Medical (APYX - Research Report) today and set a price target of $13.00. The company's shares closed yesterday at $10.28.Turkaly covers the Healthcare sector, focusing on stocks such as Apyx Medical, Haemonetics, and AxoGen. According to TipRanks, Turkaly has an average return of 6.2% and a 50.46% success rate on recommended stocks. Currently, the analyst consensus on Apyx Medical is a Strong Buy with an average price target of $14.00, which is a 36.19% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.
https://www.tipranks.com/news/blurbs/apyx-medical-apyx-receives-a-buy-from-jmp-securities-2?utm_source=advfn.com&utm_medium=referral